Viewmind
Develops non-invasive, head-mounted display (HMD) eye-tracking assessments and machine learning/statistical models to derive ocular digital biomarkers for detection, differentiation, monitoring, and quantification of neurocognitive disorders. Provides 15–20 minute assessments validated in longitudinal studies for use in clinical care, clinical trial screening and monitoring, and research collaborations.
Industries
Nr. of Employees
small (1-50)
Viewmind
Alpine, New Jersey, United States, North America
Patents
System and method for detecting neurological disorders and for measuring general cognitive performance
US-12165770-B2
View DetailsSystem and method for detecting neurological disorders and for measuring general cognitive performance
US-11694803-B2
View Details
System and method for detecting neurological disorders and for measuring general cognitive performance
US-12165770-B2
View DetailsSystem and method for detecting neurological disorders and for measuring general cognitive performance
US-11694803-B2
View DetailsProducts
HMD-delivered eye-tracking cognitive assessment
A 15–20 minute head-mounted display assessment that records eye movements and pupil responses during controlled visual tasks to generate objective neurocognitive reports.
HMD-delivered eye-tracking cognitive assessment
A 15–20 minute head-mounted display assessment that records eye movements and pupil responses during controlled visual tasks to generate objective neurocognitive reports.
Services
15-minute non-invasive pre-screening to reduce screen failure and harmonize cognitive cohorts for CNS clinical studies.
15–20 minute non-invasive assessments to quantify cognitive domains, assist differential diagnosis, and monitor treatment impact in clinical settings.
Partnerships with academic centers and clinical sites to run observational and interventional studies, and provide data analytics for biomarker validation.
Online training and certification for healthcare providers to administer assessments and interpret results.
15-minute non-invasive pre-screening to reduce screen failure and harmonize cognitive cohorts for CNS clinical studies.
15–20 minute non-invasive assessments to quantify cognitive domains, assist differential diagnosis, and monitor treatment impact in clinical settings.
Partnerships with academic centers and clinical sites to run observational and interventional studies, and provide data analytics for biomarker validation.
Online training and certification for healthcare providers to administer assessments and interpret results.
Expertise Areas
- Oculomotor digital biomarkers and digital phenotyping
- Clinical trial screening and cohort stratification for CNS studies
- Neurocognitive assessment and differential diagnosis
- Machine learning and statistical analysis of behavioral data
Key Technologies
- Eye-tracking
- Head-mounted display-based stimulus delivery
- Machine learning and statistical modeling
- Digital biomarker extraction
News & Updates
Presentation of longitudinal-study results on identification of prodromal frontotemporal dementia and differentiation from Alzheimer’s disease using ocular digital biomarkers.
Company presentations and participation at industry conferences (JPM 2024, BioFuture 2023).
Press summary of a peer-reviewed publication reporting prospective prediction of dementia from oculomotor behavior.
Discussion of the importance of early detection and the potential role of digital biomarkers in shifting diagnostics earlier in disease progression.
Publication reporting prospective prediction of conversion to Alzheimer’s with reported PPV 94% and NPV 100% in a 40-month prospective study.
Award recognition at an industry innovation competition.
Presentation of longitudinal-study results on identification of prodromal frontotemporal dementia and differentiation from Alzheimer’s disease using ocular digital biomarkers.
Company presentations and participation at industry conferences (JPM 2024, BioFuture 2023).
Press summary of a peer-reviewed publication reporting prospective prediction of dementia from oculomotor behavior.
Discussion of the importance of early detection and the potential role of digital biomarkers in shifting diagnostics earlier in disease progression.
Publication reporting prospective prediction of conversion to Alzheimer’s with reported PPV 94% and NPV 100% in a 40-month prospective study.
Award recognition at an industry innovation competition.